Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Classification and basic pathology of Alzheimer disease

Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease

Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697 · see citing works

Rapamycin alleviates toxicity of different aggregate-prone proteins

Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., Schmitt, I., Wullner, U., Evert, B. O., O'Kane, C. J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi458 · Cited by 657 · see citing works

Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing

Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617 · see citing works

Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205

Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway

Li, Y., Liu, L., Barger, S. W., & Griffin, W. S. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01605.2003 · Cited by 563 · see citing works

Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542 · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Silver staining of Alzheimer's neurofibrillary changes by means of physical development.

Gallyas, F. (1971) · PubMed · Cited by 411 · see citing works

Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes

Mercken, M. H., Vandermeeren, M., Lübke, U., Six, J., Boons, J., VOORDE, A. V. D., Martin, J., & Gheuens, J. (1992) · Acta Neuropathologica · doi:10.1007/bf00227819 · Cited by 356 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Sequential phosphorylation of Tau by glycogen synthase kinase‐3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer‐specific epitope of antibody AT100 and requires a paired‐helical‐filament‐like conformation

Zheng‐Fischhöfer, Q., Biernat, J., Mandelkow, E., Illenberger, S., Godemann, R., & Mandelkow�, E. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2520542.x · Cited by 322 · see citing works

Detection of the anti‐Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy

Dalmau, J. O., Furneaux, H., Rosenblum, M. K., Graus, F., & Posner, J. B. (1991) · Neurology · doi:10.1212/wnl.41.11.1757 · Cited by 219 · see citing works

Microglial Activation parallels System Degeneration in progressive Supranuclear palsy and Corticobasal Degeneration

Ishizawa, K., & Dickson, D. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.6.647 · Cited by 209 · see citing works

Degradation of Tau by Lysosomal Enzyme Cathepsin D: Implication for Alzheimer Neurofibrillary Degeneration

Kenessey, Á., Nacharaju, P., Ko, L., & Yen, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052026.x · Cited by 191 · see citing works

Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein

Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · see citing works

Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease

Monsonego, A., Imitola, J., Petrovic, S., Zota, V. E., Nemirovsky, A., Baron, R., Fisher, Y., Owens, T., & Weiner, H. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506209103 · Cited by 159 · see citing works

Autophagy-mediated clearance of aggresomes is not a universal phenomenon

Wong, E. S. P., Tan, J. M. M., Soong, W.-E., Hussein, K., Nukina, N., Dawson, V. L., Dawson, T. M., Cuervo, A. M., & Lim, K. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn157 · Cited by 157 · see citing works

Brain‐derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI‐3Kinase signalling mechanism

Elliott, E., Atlas, R., Lange, A. A., & Ginzburg, I. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04290.x · Cited by 142 · see citing works

Neuronal and microglial cathepsins in aging and age-related diseases

Nakanishi, H. (2003) · Ageing Research Reviews · doi:10.1016/s1568-1637(03)00027-8 · Cited by 128 · see citing works

Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations

Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700373200 · Cited by 118 · see citing works

Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice

Furlan, R. (2003) · Brain · doi:10.1093/brain/awg031 · Cited by 116 · see citing works

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury

Shein, N. A., Grigoriadis, N., Alexandrovich, A. G., Simeonidou, C., Lourbopoulos, A. I., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello, C. A., & Shohami, E. (2009) · The FASEB Journal · doi:10.1096/fj.09-134700 · Cited by 98 · see citing works

Intraneuronal IgG in the central nervous system

Fabian, R. H., & Petroff, G. (1987) · Neurology · doi:10.1212/wnl.37.11.1780 · Cited by 97 · see citing works

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics

Rosenmann, H., Grigoriadis, N., Eldar-Levy, H., Avital, A., Rozenstein‐Tsalkovich, L., Touloumi, O., Behar, L., Ben‐Hur, T., Avraham, Y., Berry, E., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.007 · Cited by 93 · see citing works

Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86 · see citing works

Ramification of microglia, monocytes and macrophages in vitro: influences of various epithelial and mesenchymal cells and their conditioned media *

Wilms, H., Hartmann, D., & Sievers, J. (1997) · Cell and Tissue Research · doi:10.1007/s004410050769 · Cited by 86 · see citing works

Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects

Rosenmann, H., Meiner, Z., Geylis, V., Abramsky, O., & Steinitz, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.072 · Cited by 77 · see citing works

The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS)

Kaye, J. F., de Rosbo, N. K., Mendel, I., Flechter, S., Hoffman, M. A., Yust, I., & Ben‐Nun, A. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00168-x · Cited by 72 · see citing works

Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?

Banks, W. A. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384862 · Cited by 58 · see citing works

Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein

Irony-Tur-Sinai, M., Grigoriadis, N., Lourbopoulos, A. I., Pinto-Maaravi, F., Abramsky, O., & Brenner, T. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.11.012 · Cited by 47 · see citing works

Phosphorylation of Tau Alters Its Association with the Plasma Membrane

Ekinci, F. J., & Shea, T. B. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007075115574 · Cited by 45 · see citing works

Uptake of antineuronal IgM by CNS neurons

Fabian, R. H. (1990) · Neurology · doi:10.1212/wnl.40.3_part_1.419 · Cited by 38 · see citing works

Inhibition of Autophagy Causes Tau Proteolysis by Activating Calpain in Rat Brain

Zhang, J. Y., Peng, C., Shi, H., Wang, S., Wang, Q., & Wang, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0908 · Cited by 34 · see citing works

Tau pathology and neurodegeneration

Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

The many faces of tau

Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · see citing works

Therapeutics of Alzheimer's disease: Past, present and future

Anand, R., Gill, K. D., & Mahdi, A. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 748 · see citing works

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · see citing works

Inflammatory process in Alzheimer's Disease

Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427 · see citing works

Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation

Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368 · see citing works

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works

A walk through tau therapeutic strategies

Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works

Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer’s Disease Brain

DeVos, S. L., Corjuc, B. T., Oakley, D. H., Nobuhara, C. K., Bannon, R. N., Chase, A., Commins, C., Gonzalez, J. A., Dooley, P. M., Frosch, M. P., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00267 · Cited by 285 · see citing works

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · see citing works

Inhibition of Amyloid Formation

Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 266 · see citing works

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · see citing works

Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease

Nakamura, K., Greenwood, A., Binder, L. I., Bigio, E. H., Denial, S., Nicholson, L. K., Zhou, X. Z., & Lu, K. P. (2012) · Cell · doi:10.1016/j.cell.2012.02.016 · Cited by 255 · see citing works

Protein phosphorylation in neurodegeneration: friend or foe?

Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252 · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works

Developing Therapeutic Antibodies for Neurodegenerative Disease

Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227 · see citing works

Constitutive secretion of tau protein by an unconventional mechanism

Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224 · see citing works

Tau in neurodegenerative disease

Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222 · see citing works

Intersection of pathological tau and microglia at the synapse

Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197 · see citing works

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works

Tau passive immunization inhibits not only tau but also Aβ pathology

Dai, C., Tung, Y. C., Liu, F., Gong, C., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 186 · see citing works

Anti‐tau antibody reduces insoluble tau and decreases brain atrophy

Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185 · see citing works

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184 · see citing works

Transgenic mouse models of alzheimer disease: Developing a better model as a tool for therapeutic interventions.

Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178 · see citing works

Protein aggregation and neurodegenerative diseases: From theory to therapy

Kumar, V., Sami, N., Kashav, T., Islam, A., Ahmad, F., & Hassan, M. I. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.054 · Cited by 176 · see citing works

Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease

Bakota, L., & Brandt, R. (2016) · Drugs · doi:10.1007/s40265-015-0529-0 · Cited by 170 · see citing works

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 163 · see citing works

Tissue-nonspecific Alkaline Phosphatase Promotes the Neurotoxicity Effect of Extracellular Tau

Dı́az-Hernández, M., Gómez‐Ramos, A., Rubio, A., Gómez‐Villafuertes, R., Naranjo, J. R., Miras‐Portugal, M. T., & Ávila, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145003 · Cited by 154 · see citing works

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4989-14.2015 · Cited by 149 · see citing works

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

Sankaranarayanan, S., Barten, D. M., Vana, L., Devidze, N., Yang, L., Cadelina, G. W., Hoque, N., DeCarr, L. B., Keenan, S., Lin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125614 · Cited by 143 · see citing works

Therapeutic strategies for tau mediated neurodegeneration

Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 129 · see citing works

“Prion‐Like” Templated Misfolding in Tauopathies

Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., & Tolnay, M. (2013) · Brain Pathology · doi:10.1111/bpa.12044 · Cited by 129 · see citing works

Tau‐targeted treatment strategies in Alzheimer's disease

Götz, J., Ittner, A., & Ittner, L. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01713.x · Cited by 127 · see citing works

Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders

Alajangi, H. K., Kaur, M., Sharma, A., Rana, S., Thakur, S., Chatterjee, M., Singla, N., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00937-4 · Cited by 130 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro

Nobuhara, C. K., DeVos, S. L., Commins, C., Wegmann, S., Moore, B. D., Roe, A. D., Costantino, I., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.01.022 · Cited by 120 · see citing works

The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology

Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120 · see citing works

New perspectives on the role of tau in Alzheimer's disease. Implications for therapy

Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 118 · see citing works

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 116 · see citing works

Tau as a therapeutic target in neurodegenerative disease

Himmelstein, D. S., Ward, S., Lancia, J. K., Patterson, K. R., & Binder, L. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.001 · Cited by 113 · see citing works

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease

Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt277 · Cited by 112 · see citing works

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 112 · see citing works

Progressive supranuclear palsy: Advances in diagnosis and management

Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 113 · see citing works

Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity

Ando, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005917 · Cited by 105 · see citing works

Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review

Boutajangout, A., & Wısnıewskı, T. (2014) · Gerontology · doi:10.1159/000358875 · Cited by 105 · see citing works

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau

Yang, H., Sun, Z., & Chen, S. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-21 · Cited by 102 · see citing works

Slow Excitotoxicity in Alzheimer's Disease

Ong, W.-Y., Tanaka, K., Dawe, G. S., Ittner, L. M., & Farooqui, A. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121990 · Cited by 101 · see citing works

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 97 · see citing works

Active immunotherapy options for Alzheimer’s disease

Winblad, B. G., Graf, A., Riviere, M., Andreasen, N., & Ryan, J. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt237 · Cited by 100 · see citing works

The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target

Wolfe, M. S. (2012) · Scientifica · doi:10.6064/2012/796024 · Cited by 97 · see citing works

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy

Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 91 · see citing works

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 90 · see citing works

The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics

Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89 · see citing works

Microglia in action: how aging and injury can change the brain’s guardians

Lourbopoulos, A. I., Ertürk, A., & Hellal, F. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00054 · Cited by 89 · see citing works

Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease

Driver, J. A., Zhou, X. Z., & Lu, K. P. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.12.025 · Cited by 89 · see citing works

Emerging Therapeutics for Alzheimer's Disease

Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 88 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works

TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits

Wang, H., Wang, R., Carrera, I., Xu, S., & Lakshmana, M. K. (2016) · eNeuro · doi:10.1523/eneuro.0042-16.2016 · Cited by 76 · see citing works

Passive immunotherapy of tauopathy targeting pSer413‐tau: a pilot study in mice

Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., & Tomiyama, T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.171 · Cited by 73 · see citing works

Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species

Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 73 · see citing works

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

Krishnamurthy, P., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 71 · see citing works

FTD and ALS—translating mouse studies into clinical trials

Ittner, L. M., Halliday, G. M., Kril, J. J., Götz, J., Hodges, J. R., & Kiernan, M. C. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.65 · Cited by 69 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67 · see citing works

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · see citing works

Antibody-DerivedIn VivoImaging of Tau Pathology

Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62 · see citing works

A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 65 · see citing works

Active poly‐GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model

Zhou, Q., Mareljic, N., Michaelsen, M., Parhizkar, S., Heindl, S., Nuscher, B., Farny, D., Czuppa, M., Schludi, C., Graf, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910919 · Cited by 62 · see citing works

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target

Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 57 · see citing works

Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies

Clavaguera, F., Grueninger, F., & Tolnay, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.037 · Cited by 60 · see citing works

Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models

Acker, C. M., Forest, S. K., Zinkowski, R., Davies, P., & d’Abramo, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.010 · Cited by 58 · see citing works

Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity

Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58 · see citing works

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., & LaFerla, F. M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.047 · Cited by 58 · see citing works

Antibody-based therapy in Alzheimer's disease

Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58 · see citing works

Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament

Bartoš, A., Fialová, L., Švarcová, J., & Řı́pová, D. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.08.001 · Cited by 57 · see citing works

Targeting tauopathy with engineered tau-degrading intrabodies

Gallardo, G., Wong, C. H. Y., Hernandez, S. M. R., Mann, C. N., Lin, K., Leyns, C. E. G., Jiang, H., & Holtzman, D. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0340-6 · Cited by 55 · see citing works

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 53 · see citing works

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau

Strang, K. H., Goodwin, M. S., Riffe, C. J., Moore, B. D., Chakrabarty, P., Levites, Y., Golde, T. E., & Giasson, B. I. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0458-0 · Cited by 52 · see citing works

Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau

Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 51 · see citing works

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49 · see citing works

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

Schroeder, S. K., Joly‐Amado, A., Gordon, M. N., & Morgan, D. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9637-6 · Cited by 49 · see citing works

The P2X7 receptor: a new therapeutic target in Alzheimer’s disease

Illés, P., Rubini, P., Huang, L., & Tang, Y. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1575811 · Cited by 49 · see citing works

The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration

Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 44 · see citing works

Advances in tau-based drug discovery

Noble, W. J., Pooler, A. M., & Hanger, D. P. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586690 · Cited by 44 · see citing works

Vaccination strategies in tauopathies and synucleinopathies

Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 43 · see citing works

Further understanding of tau phosphorylation: implications for therapy

Medina, M., & Avila, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1000864 · Cited by 41 · see citing works

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Selenica, M.-L. B., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0152-0 · Cited by 40 · see citing works

Invited review: Drug development for tauopathies

Grüninger, F. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12192 · Cited by 40 · see citing works

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.579099 · Cited by 38 · see citing works

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 39 · see citing works

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease

Lambracht‐Washington, D., & Rosenberg, R. N. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31428 · Cited by 38 · see citing works

Moderate Environmental Enrichment Mitigates Tauopathy in a Neurofibrillary Tangle Mouse Model

Lahiani-Cohen, I., Lourbopoulos, A. I., Haber, E., Rozenstein‐Tsalkovich, L., Abramsky, O., Grigoriadis, N., & Rosenmann, H. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318221bfab · Cited by 37 · see citing works

S4‐04‐08: Immunotherapy Targeting Pathologically Phosphorylated Tau in a Tauopathy Mouse Model

Boimel, M., Grigoriadis, N., Lourbopoulos, A. I., Haber, E., Abramsky, O., & Rosenmann, H. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.135

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · see citing works

Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies

Rosenmann, H. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030001 · Cited by 52 · see citing works

P2‐387: Phospho‐tau–specific vaccine for the treatment of tau pathology

Adolfsson, O., Gafner, V., Theunis, C., Pihlgren, M., Crespo‐Biel, N., Papin, S., López-Deber, M. P., Borghgraef, P., Piorkowska, K., Devijver, H., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1097

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model

Theunis, C., Crespo‐Biel, N., Pihlgren, M., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., Borghgraef, P., Devijver, H., et al. (2013)